Cocrystal systems of pharmaceutical interest: 2007-2008

Profiles of Drug Substances, Excipients and Related Methodology

Volumn 35, Issue , 2010, Pages 373-390

  Brittain, Harry G ^a  

^a Center for Pharmaceutical Physics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79957939298     PISSN: 18715125     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1871-5125(10)35009-6     Document Type: Chapter

References (75)

1. Byrn S.R., Pfeiffer R.R., Stowell J.G. Solid State Chemistry of Drugs 1999, SSCI Inc., West Lafayette. third ed.
2. Brittain H.G. Polymorphism in Pharmaceutical Solids 1999, Marcel Dekker, New York. first ed.
3. Bernstein J. Polymorphism in Molecular Crystals 2002, Clarendon Press, Oxford.
4. Hilfiker R. Polymorphism in the Pharmaceutical Industry 2006, Wiley-VCH, Weinheim.
5. Brittain H.G. Polymorphism in Pharmaceutical Solids 2009, Informa Healthcare Press, New York. second ed.
6. Brittain H.G. Polymorphism and Solvatomorphism 2004. Profiles of Drug Substances, Excipients, and Related Methodology 2005, vol. 32:263-283. Elsevier Academic Press, Amsterdam.
7. Brittain H.G. Polymorphism and solvatomorphism 2005. J. Pharm. Sci. 2007, 96:705-728.
8. Brittain H.G. Polymorphism and solvatomorphism 2006. J. Pharm. Sci. 2008, 97:3611-3636.
9. Brittain H.G. Polymorphism and solvatomorphism 2007. J. Pharm. Sci. 2009, 98:1617-1642.
10. Brittain H.G. Polymorphism and solvatomorphism 2008. J. Pharm. Sci. 2010, 99. accepted for publication (2010).
11. Vishweshwar P., McMahon J.A., Bis J.A., Zaworotko M.J. Pharmaceutical cocrystals. J. Pharm. Sci. 2006, 95:499-516.
12. Zaworotko M.J. Molecules to crystals, crystals to molecules . . . and back again?. Cryst. Growth Des. 2007, 7:4-9.
13. Aakeröy C.B., Salmon D.J. Building co-crystals with molecular sense and supramolecular sensibility. Cryst. Eng. Comm. 2005, 7:439-448.
14. Desiraju G.R. Supramolecular synthons in crystal engineering: a new organic synthesis. Angew. Chem. Int. Ed. 1995, 34:2311-2327.
15. Leiserowitz L., Nader F. The molecular packing modes and the hydrogen-bonding properties of amide:dicarboxylic acid complexes. Acta Cryst. 1977, B33:2719-2733.
16. Reddy L.S., Nangia A., Lynch V.M. Phenyl-perfluorophenyl synthon mediated cocrystallization of carboxylic acids and amides. Cryst. Growth Des. 2004, 4:89-94.
17. Janowski W., Gdaniec M., Połoński T. The 2:1 cocrystal of benzamide and pentafluorobenzoic acid. Acta Cryst. 2006, C62:o492-o494.
18. Childs S.L., Stahly G.P., Park A. The salt-cocrystal continuum: the influence of crystal structure on ionization state. Mol. Pharm. 2007, 4:323-338.
19. Stahly G.P. Diversity in single- and multiple-component crystals: the search for and prevalence of polymorphs and cocrystals. Cryst. Growth Des. 2007, 7:1007-1026.
20. Aakeröy C.B., Fasulo M.E., Desper J. Cocrystal or salt: does it really matter?. Mol. Pharm. 2007, 4:317-322.
21. Caira M.R. Sulfa drugs as model cocrystal formers. Mol. Pharm. 2007, 4:310-316.
22. Basavoju S., Boström D., Velga S.P. Pharmaceutical cocrystal and salts of norfloxacin. Cryst. Growth Des. 2006, 6:2699-2708.
23. Aakeröy C.B., Desper J., Fasulo M., Hussain I., Levin B., Schultheiss N. Ten years of cocrystalsynthesis: the good, the bad, and the ugly. CrystEngComm 2008, 10:1816-1821.
24. Shan N., Zaworotko M.J. The role of cocrystals in pharmaceutical science. Drug Discov. Today 2008, 13:440-446.
25. Pedireddi V.R., Jones W., Chorlton A.P., Docherty R. Creation of crystalline supramolecular arrays: a comparison of cocrystal formation from solution and by solid-state grinding. Chem. Commun. 1996, 987-988.
26. Shan N., Toda F., Jones W. Mechanochemistry and co-crystal formation: effect of solvent on reaction kinetics. Chem. Commun. 2002, 2372-2373.
27. Trask A.V., Motherwell W.D.S., Jones W. Solvent-drop grinding: green polymorph control of cocrystallization. Chem. Commun. 2004, 890-891.
28. Trask A.V., Shan N., Motherwell W.D.S., Jones W., Feng S., Tan R.B.H., Carpenter K.J. Selective polymorph transformation via solvent-drop grinding. Chem. Commun. 2005, 880-882.
29. Trask A.V., Motherwell W.D.S., Jones W. Crystal engineering of organic cocrystals by the solid-state grinding approach. Top. Curr. Chem. 2005, 254:41-70.
30. Jayasankar A., Somwangthanaroj A., Shao Z.J., Rodríguez-Hornedo N. Cocrystal formation during cogrinding and storage is mediated by amorphous phase. Pharm. Res. 2006, 23:2381-2392.
31. Jayasankar A., Good D.J., Rodríguez-Hornedo N. Mechanism by which moisture generates cocrystals. Mol. Pharm. 2007, 4:360-372.
32. Karki S., Frišić T., Jones W., Motherwell W.D.S. Screening for pharmaceutical cocrystal hydrates via neat and liquid-assisted grinding. Mol. Pharm. 2007, 4:347-354.
33. Zhang G.G.Z., Henry R.F., Borchardt T.B., Lou X. Efficient co-crystal screening using solution-mediated phase transformation. J. Pharm. Sci. 2007, 96:990-995.
34. Nehm S.J., Rodríguez-Spong B., Rodríguez-Hornedo N. Phase solubility diagrams of cocrystals are explained by solubility product and solution complexation. Cryst. Growth Des. 2006, 6:592-600.
35. Childs S.L., Rodríguez-Hornedo N., Reddy L.S., Jayasankar A., Maheshwari C., McCausland L., Shipplett R., Stahly B.C. Screening strategies based on solubility and solution composition generate pharmaceutically acceptable cocrystals of carbamazepine. CrystEngComm 2008, 10:856-864.
36. McNamara D.P., Childs S.L., Giordano J., Iarriccio A., Cassidy J., Shet M.S., Mannion R., O'Donnell E., Park A. Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API. Pharm. Res. 2006, 23:1888-1897.
37. Berry D.J., Seaton C.C., Clegg W., Harrington R.W., Coles S.J., Horton P.N., Hursthouse M.B., Storey R., Jones W., Frii T., Blagden N. Applying hot-stage microscopy to co-crystal screening: a study of nicotinamide with seven active pharmaceutical ingredients. Cryst. Growth Des. 2008, 8:1697-1712.
38. Lu E., Rodríguez-Hornedo N., Suryanarayanan R. A rapid thermal method for cocrystal screening. CrystEngComm 2008, 10:665-668.
39. Stahly G.P. Diversity in single- and multiple-component crystals. The search for and prevalence of polymorphs and cocrystals. Cryst. Growth Des. 2007, 7:1007-1026.
40. He G., Jacob C., Guo L., Chow P.S., Tan R.B.H. Screening for cocrystallization tendency: the role of intermolecular interactions. J. Phys. Chem. B 2008, 112:9890-9895.
41. Fleischman S.G., Kuduva S.S., McMahon J.A., Moullton B., Walah R.D.B., Rodríguez-Hornedo N., Zaworotko M.J. Crystal engineering of the composition of pharmaceutical phases: multiple-component crystalline solids involving carbamazepine. Cryst. Growth Des. 2003, 3:909-919.
42. Nehm S.J., Rodríguez-Spong B., Rodríguez-Hornedo N. Phase solubility diagrams of cocrystals are explained by solubility product and solution complexation. Cryst. Growth Des. 2006, 6:592-600.
43. Rodríguez-Hornedo N., Nehm S.J., Seefeldt K.F., Pagán-Torres Y., Falkiewicz C.J. Reaction crystallization of pharmaceutical molecular complexes. Mol. Pharm. 2006, 3:362-367.
44. Seefeldt K., Miller J., Alvarez-Núñez F., Rodríguez-Hornedo N. Crystallization pathways and kinetics of carbamazepine-nicotinamide cocrystals from the amorphous state by in situ thermomicroscopy, spectroscopy, and calorimetry studies. J. Pharm. Sci. 2007, 96:1147-1158.
45. ter Horst J.H., Cains P.W. Cocrystal polymorphs from a solvent-mediated transformation. Cryst. Growth Des. 2008, 8:2537-2542.
46. Porter W.W., Elie S.C., Matzger A.J. Polymorphism in carbamazepine cocrystals. Cryst. Growth Des. 2008, 8:14-16.
47. Hickey M.B., Peterson M.L., Scoppettuolo L.A., Morrisette S.L., Vetter A., Guzmán H., Remenar J.F., Zhang Z., Tawa M.D., Haley S., Zaworotko M.J., Almarsson Ö. Performance comparison of a co-crystal of carbamazepine with marketed product. Eur. J. Pharm. Biopharm. 2007, 67:112-119.
48. Cabeza A.J.C., Day G.M., Motherwell W.D.S., Jones W. Importance of molecular shape for the overall stability of hydrogen bond motifs in the crystal structures of various carbamazepine-type drug molecules. Cryst. Growth Des. 2007, 7:100-107.
49. Johnston A., Florence A.J., Fabbiani F.J.A., Shankland K., Bedford C.T., Bardin J. Cytenamide trifluoroacetic acid solvate. Acta Cryst. 2008, E64:o1215-o1216.
50. Johnston A., Florence A.J., Fabbiani F.J.A., Shankland K., Bedford C.T. Cytenamide-butyric acid (1/1). Acta Cryst. 2008, E64:o1295-o1296.
51. Johnston A., Florence A.J., Fabbiani F.J.A., Shankland K., Bedford C.T. Cytenamide-1, 4-dioxane (2/1). Acta Cryst. 2008, E64:o1345-o1346.
52. Johnston A., Florence A.J., Miller F.J., Kennedy A.R., Bedford C.T. Cytenamide-formic acid (1/1). Acta Cryst. 2008, E64:o1379-o1380.
53. Reddy L.S., Nangia A., Lynch V.M. Phenyl-perfluorophenyl synthon mediated cocrystallization of carboxylic acids and amides. Cryst. Growth Des. 2004, 4:89-94.
54. Oberoi L.M., Alexander K.S., Riga A.T. Study of interaction between ibuprofen and nicotinamide using differential scanning calorimetry, spectroscopy, and microscopy and formulation of a fast-acting and possibly better ibuprofen suspension for osteoarthritis patients. J. Pharm. Sci. 2005, 94:93-101.
55. Remenar J.F., Peterson M.L., Stephens P.W., Zhang Z., Zimenkov Y., Hickey M.B. Celecoxib:nicotinamide dissociation: using excipients to capture the cocrystal's potential. Mol. Pharm. 2007, 4:386-400.
56. Nicoli S., Bilzi S., Santi P., Caira M.R., Li J., Bettini R. Ethyl-paraben and nicotinamide mixtures: apparent solubility, thermal behavior and X-ray structure of the 1:1 cocrystal. J. Pharm. Sci. 2008, 97:4830-4839.
57. Chiarella R.A., Davey R.J., Peterson M.L. Making cocrystals-the utility of ternary phase diagrams. Cryst. Growth Des. 2007, 7:1223-1226.
58. Lemmerer A., Báthori N.B., Bourne S.A. Chiral carboxylic acids and their effects on melting-point behavior in cocrystals with isonicotinamide. Acta Cryst. 2008, B64:780-790.
59. Seaton Colin C., Parkin Andrew, Wilson Chick C., Blagden Nicholas Growth of an organic cocrystal upon a component subphase. Cryst Growth Des. 2008, 8:363-368.
60. Aakeröy C.B., Beatty A.M., Helfrich B.A. A high-yielding supramolecular reaction. J. Am. Chem. Soc. 2002, 124:14425-14432.
61. Oliveira M.A., Peterson M.L., Klein D. Continuously substituted solid solutions of organic cocrystals. Cryst. Growth Des. 2008, 8:4487-4493.
62. Trask A.V., van de Streek J., Motherwell W.D.S., Jones W. Achieving polymorphic and stoichiometric diversity in cocrystal formation: importance of solid-state grinding, powder X-ray structure determination, and seeding. Cryst. Growth Des. 2005, 5:2233-2241.
63. Buar D.-K., Henry R.F., Lou X., Duerst R.W., Borchardt T.B., MacGillivray L.R., Zhang G.G.Z. Cocrystals of caffeine and hydroxy-2-naphthoic acids: unusual formation of the carboxylic acid dimer in the presence of a heterosynthon. Mol. Pharm. 2007, 4:339-346.
64. Frii T., Trask A.V., Motherwell W.D.S., Jones W. Guest-directed assembly of caffeine and succinic acid into topologically different heteromolecular host networks upon grinding. Cryst. Growth Des. 2008, 8:1605-1609.
65. Sun C.C., Hou H. Improving mechanical properties of caffeine and methyl gallate crystals by cocrystallization. Cryst. Growth Des. 2008, 8:1575-1579.
66. Trask A.V., Motherwell W.D.S., Jones W. Physical stability enhancement of theophylline via cocrystallization. Int. J. Pharm. 2006, 320:114-123.
67. Wang Z.-L., Wei L.-H. Theophylline-2,4-dihydroxybenzoic acid-water (1/1/1). Acta Cryst. 2007, E63:o1681-o1682.
68. Bhatt P.M., Ravindra N.V., Banerjee R., Desiraju G.R. Saccharin as a salt former. Enhanced solubilities of saccharinates of active pharmaceutical ingredients. Chem. Comm. 2005, 1073-1075.
69. Banerjee R., Bhatt P.M., Ravindra N.V., Desiraju G.R. Saccharin salts of active pharmaceutical ingredients, their crystal structures, and increased water solubilities. Cryst. Growth Des. 2005, 5:2299-2309.
70. Basavoju S., Boström D., Velaga S.P. Indomethacin-saccharin cocrystal: design, synthesis and preliminary pharmaceutical characterization. Pharm. Res. 2008, 25:530-541.
71. Shiraki K., Takata N., Takano R., Hayashi Y., Terada K. Dissolution improvement and the mechanism of the improvement from cocrystallization of poorly water-soluble compounds. Pharm. Res. 2008, 25:2581-2592.
72. Shattock T.R., Arora K.K., Vishweshwar P., Zaworotko M.J. Hierarchy of supramolecular synthons: persistent carboxylic acid pyridine hydrogen bonds in cocrystals that also contain a hydroxyl moiety. Cryst. Growth Des. 2008, 8:4533-4545.
73. Childs S.L., Hardcastle K.I. Cocrystals of piroxicam with carboxylic acids. Cryst. Growth Des. 2007, 7:1291-1304.
74. Wenger M., Bernstein J. An alternate crystal form of gabapentin: a cocrystal with oxalic acid. Cryst. Growth Des. 2008, 8:1595-1598.
75. Polito M., D'Oria E., Maini L., Karamertzanis P.G., Grepioni F., Braga D., Price S.L. The crystal structures of chloro and methyl ortho-benzoic acids and their co-crystal: rationalizing similarities and differences. CrystEngComm 2008, 10:1848-1854.